Ani pharmaceuticals announces the fda approval and launch of l-glutamine oral powder

Princeton, n.j., july 15, 2024 (globe newswire) -- ani pharmaceuticals, inc. (ani or the company) (nasdaq: anip) today announced that following final approval from the u.s. food and drug administration (fda) for its abbreviated new drug application (anda), the company launched l-glutamine oral powder. ani's l-glutamine oral powder is the generic version of the reference listed drug (rld) endari®.
ANIP Ratings Summary
ANIP Quant Ranking